Janssen’s Esketamine Gets US FDA Panel Endorsement, But With Pricing, Access And Diversion Concerns

Committee overwhelmingly supports approval for treatment-resistant depression but warns that pricing and combination therapy indication could hinder patient access. Esketamine’s risks of sedation and dissociative effects, and its abuse potential, will necessitate a strict risk management strategy.

Depression or nervous breakdown disorder of mental health psychotherapy diagnosis for therapy depression.

A US FDA advisory committee endorsed Janssen R&D LLC’s esketamine as a potentially game-changing therapy for treatment-resistant depression but also identified some commercial challenges for the sponsor.

Members of the Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee on Feb. 12 pointed to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip